Company intelligence / Profile preview

Bio Vitos Pharma

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

Bio Vitos Pharma commercializes Helge®, an innovative near-patient diagnostic device for detecting hemolysis in blood samples. The solution aims to reduce unnecessary repeat blood draws due to undetected hemolysis, improving patient flow and clinical decision-making. The company serves emergency departments across the EU and US.

Therapeutic areas: Hematology
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

KFUM Kalmar – research study collaboration

Beyond the preview

Go deeper on Bio Vitos Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio Vitos Pharma.

Explore the full profile